MEDO Technologies, Inc. reported a net loss of $191,301 for the three months ended September 30, 2026, and a cumulative net loss of $400,884 for the nine-month period. The company remains in a deficit position with total stockholders' deficit of $395,563 and implemented a 1-for-100,000 reverse stock split effective September 23, 2026.
Columbus Circle Capital Corp III is a shell company that completed its IPO on July 10, 2026, raising $230 million held in a trust account. As of September 30, 2026, the company has 23,665,000 Class A and 7,666,667 Class B ordinary shares outstanding and is seeking a business combination within a 24-month period.
SmartKem, Inc. reported a net loss of $24.1 million for the nine months ended September 30, 2026, significantly impacted by a $45.6 million loss on the write-off of bad debts and $11.9 million in ELOC commitment share expenses. Despite these losses, the company improved its balance sheet through debt-to-equity conversions and preferred stock issuances, ending the period with $4.3 million in cash and total stockholders' equity of $12.8 million.
Our Bond, Inc. reported a significant increase in net loss to $16.1 million for the nine months ended September 30, 2026, compared to $7.8 million in the prior year, driven by a doubling of operating expenses. Revenue slightly declined to $6.98 million, while the company maintained a stockholders' deficit of $16.97 million.
CERo Therapeutics Holdings, Inc. is an emerging growth company focused on developing its lead product candidate, CER-1236. As of November 13, 2026, the company reported 83,309,742 shares of common stock outstanding and noted the impact of its delisting from Nasdaq as a significant risk factor.
For the nine months ended September 30, 2026, CIFC Direct Lending Evergreen Fund reported total investment income of $22.8 million and net investment income of $10.3 million. Total net assets grew to $112.1 million, supported by $11.0 million in net increase from operations and $9.0 million in capital contributions, partially offset by $9.9 million in distributions and redemptions.
OptimizeRx reported Q3 2026 revenue of $21.6 million, a 17% year-over-year decrease, while GAAP net income rose to $1.2 million. The company updated its full-year 2026 revenue guidance to $87-$93 million but maintained its adjusted EBITDA outlook. Management highlighted significant margin expansion and a reduction in debt principal to $10.4 million.
Term
Q3 2026
“Third quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and the resilience of our operating model. While revenue declined year-over-year, adjusted EBITDA increased approximately 23%, with adjusted EBITDA margins expanding over 900 basis points, demonstrating the benefits of our improved product mix and cost management initiatives.”
Stephen L. Silvestro, OptimizeRx CEO
“While in-year contracted revenue continues to track below prior-year levels, resulting in a revision to our full-year 2026 revenue outlook, we remain encouraged by the growth we are seeing in contracted revenue for 2027, highlighting a start to a strong RFP season.”
For the nine months ended September 30, 2026, FB Bancorp reported net income of $515 thousand, a significant decrease from $2.66 million in the prior year period, primarily due to a $1.14 million loss from discontinued operations and increased non-interest expenses. Total assets decreased to $1.21 billion from $1.26 billion at year-end 2025, while stockholders' equity was impacted by $32.3 million in common stock repurchases.
Yorkville International Capital Corp. is a special purpose acquisition company (SPAC) that completed its IPO on June 17, 2026, raising $230 million held in a trust account. As of September 30, 2026, the company is in its search phase for an initial business combination and reported 23,000,000 Class A and 15,333,333 Class B ordinary shares outstanding.
TRG Latin America Acquisitions Corp. is a special purpose acquisition company (SPAC) that completed its IPO on February 27, 2026, raising proceeds for a trust account totaling $210,677,645 as of September 30, 2026. The company is currently in its combination period with a deadline of February 27, 2028, to consummate an initial business combination.
Pony Group Inc. reported a net loss of $147,554 for the nine months ended September 30, 2026, compared to a loss of $115,100 in the prior year period. Total revenue decreased slightly to $97,880 from $104,137, while the company continues to operate with a significant stockholders' deficit of $1,100,109.
Owlet, Inc. reported 29,889,307 shares of Class A Common Stock outstanding as of November 9, 2026. The filing highlights significant risks including a history of losses, reliance on single manufacturers for key products like Dream Sock and Owlet Cam, and a recent camera cable guard safety update and stop sale initiated in November 2026.
Curis reported financial results for the third quarter of 2026 and provided an operational update on its TakeAim CLL and TakeAim Lymphoma clinical trials. The company highlighted progress in combining emavusertib with BTK inhibitors for the treatment of CLL and PCNSL, with initial data from the TakeAim CLL study expected in December 2026.
Term
Q3 2026
“The excitement among clinicians and patients reflects the clear unmet need in both CLL and PCNSL, where emavusertib has the potential to change the treatment landscape when combined with approved BTK inhibitors.”
TherapeuticsMD reported third quarter 2026 financial results, highlighting license revenue of $1.3 million, a 60.6% increase year-over-year. The company achieved a $0.5 million net income from continuing operations and ended the period with $10.4 million in cash. Management noted the achievement of a sales-based milestone for IMVEXXY and continues to evaluate strategic alternatives including potential mergers or asset sales.
Espey Mfg. & Electronics Corp. reported net sales of $10.6 million for the quarter ended September 30, 2026, a 16.7% increase over the prior year. Despite higher sales, net income remained relatively flat at $2.19 million due to increased cost of sales and lower interest income.
BullFrog AI Holdings, Inc. reported a net loss of $4,976,572 for the nine months ended September 30, 2026, compared to a loss of $5,017,894 in the prior year period. While collaboration revenue increased to $278,963, the company continues to incur significant operating expenses primarily driven by general and administrative costs and research and development.
OptimumBank Holdings, Inc. reported a significant increase in net income to $18.5 million for the nine months ended September 30, 2026, compared to $11.8 million in the prior year. Total assets grew to $1.58 billion, driven by a substantial increase in the loan portfolio and the issuance of $34.4 million in subordinated debt.
Skye Bioscience reported a significant decrease in cash and short-term investments from $25.7 million at year-end 2025 to $4.8 million as of September 30, 2026. The company experienced a net loss of $23.2 million for the first nine months of 2026, driven primarily by $13.2 million in research and development expenses. A 1-for-8 reverse stock split was effected on August 24, 2026.
National Presto Industries reported a significant increase in net earnings for the nine months ended October 4, 2026, reaching $42.5 million compared to $18.1 million in the prior year period. This growth was driven by a 20.6% increase in net sales to $409.6 million and improved gross profit margins, alongside a $1.7 million gain from the sale of property, plant, and equipment.
AB Private Lending Fund reported a net increase in net assets resulting from operations of $8.86 million for the nine months ended September 30, 2026, compared to $9.22 million in the prior year period. Total investment income grew to $25.86 million, though net investment income per share decreased from $1.86 to $1.69 due to a higher weighted average share count.
First National Corp reported net income of $1.25 per share for both the third quarter and the first nine months of 2026. The company maintained stable dividend payouts and saw a slight increase in total assets compared to the prior year-end, supported by growth in interest and fees on loans.
Enveric Biosciences reported financial results for the third quarter of 2026 and provided a corporate update on its lead candidate EB-003. The company is completing final IND-enabling activities for EB-003, a non-hallucinogenic neuroplastogenic candidate, with plans for an IND submission and Phase 1 clinical trial.
Term
Q3 2026
“Our focus during the third quarter was advancing final IND-enabling activities for EB-003 as we prepare for the planned IND submission and first-in-human Phase 1 clinical trial of our lead non-hallucinogenic, neuroplastogenic candidate.”
Joseph Tucker, Ph.D., Chief Executive Officer of Enveric
“The growing body of preclinical evidence reinforces our confidence in this opportunity as we complete the final IND-enabling activities and prepare to advance EB-003 toward first-in-human clinical development.”
Joseph Tucker, Ph.D., Chief Executive Officer of Enveric
Aptera Motors reported a GAAP net loss of $14.0 million for the third quarter of 2026, with research and development spending more than doubling year-over-year. The company ended the quarter with $9.2 million in cash and highlighted a new strategic partnership with Shanghai Launch Automotive Technology to support manufacturing and contract engineering.
Term
Q3 2026
“In the third quarter we started the process of procuring parts for our first production vehicles. We also entered into a strategic partnership with Launch to support manufacturing and contract engineering, which we believe has helped lower our estimated capital needs to reach start of production and, most importantly, the capital we estimate is required to reach a production rate at which we believe we could fund ongoing operations from vehicle sales.”
SenesTech, Inc. reported a net loss of $5.85 million for the nine months ended September 30, 2026, compared to $4.58 million in the prior year period, despite a 31% increase in total revenues to $2.36 million. The company's cash position decreased to $3.95 million, and management indicated that current resources are only sufficient to fund operations for approximately nine months from the filing date.
For the nine months ended September 30, 2026, the WisdomTree Bitcoin Fund reported a net decrease in net assets resulting from operations of $1,601,685, primarily driven by a net change in unrealized depreciation on bitcoin. Despite the operational loss, net assets grew to $171.9 million from $139.7 million at the start of the year, bolstered by $33.9 million in net capital share transactions.
Amesite Inc. reported a net loss of $774,395 for the quarter ended September 30, 2026, compared to a loss of $642,266 in the prior year period, driven by increased technology and content development costs. The company's management expressed substantial doubt about its ability to continue as a going concern, noting that current cash reserves may not sustain operations for the next twelve months.
The Morgan Stanley Bitcoin Trust commenced operations on April 7, 2026, and reported net assets of $873.4 million as of September 30, 2026. For the period from inception through September 30, 2026, the Trust saw a net increase in net assets from operations of $96.6 million, primarily driven by $97.5 million in unrealized appreciation on its bitcoin holdings.
High Roller Technologies reported a net loss of $7.1 million for the nine months ended September 30, 2026, compared to a net loss of $0.2 million in the prior year period. Revenues decreased significantly from $15.8 million to $8.6 million year-over-year, while the company successfully completed an offering that increased cash and cash equivalents to $13.4 million.
Carlyle Credit Solutions reported total investment income of $66.7 million for the quarter ended September 30, 2026, and net investment income of $38.3 million. Total net assets decreased slightly to $1.74 billion from $1.77 billion at year-end 2025, primarily driven by $51.7 million in net unrealized depreciation on investments and $129.7 million in distributions to stockholders.
AmperCap Acquisition Co's 10-Q filing for the period ending September 30, 2026, reflects its status as a blank check company with no current operations. The report details administrative expenses and interest income generated from the trust account as the company continues to evaluate potential business combination targets. No definitive merger agreements or significant changes in financial guidance were disclosed.